export default function AbaloparatideOverviewPanel() {
  return (
    <div className="reta-overview">

      <p className="reta-overview__opener">
        Abaloparatide (brand name Tymlos) is a prescription drug that rebuilds bone — not just slows its loss, but actually makes new bone — in people with severe osteoporosis who are at high risk of breaking something. It&rsquo;s a daily injection, available only through a doctor, and it&rsquo;s genuinely effective for that narrow purpose. Outside of medically supervised osteoporosis treatment, there is no established use case.
      </p>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 1</div>
        <h3 className="reta-overview__profile-heading">The Patient — Someone managing osteoporosis or serious bone-loss concerns</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;My doctor mentioned this as an option for my osteoporosis. Is it actually better than the pills I&rsquo;ve been taking, and what am I signing up for?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>It builds bone, not just protects it</strong><br />Most osteoporosis medications work by slowing the process that breaks down bone. Abaloparatide does something rarer — it directly stimulates new bone formation. For someone with severely thinned bones who has already fractured, that active building is a meaningful distinction. The clinical trial showed vertebral fracture rates dropping from over 4% to under 1% over 18 months.</li>
          <li><strong>A clear treatment pathway with consolidation</strong><br />Abaloparatide is designed as a 12 to 24 month &ldquo;builder&rdquo; phase, after which patients transition to a different medication that preserves those gains. When done right, you get the density increases and then lock them in. That sequential plan gives patients a concrete framework rather than indefinite medication.</li>
          <li><strong>More bone-focused than teriparatide</strong><br />The older bone-building drug in this class, teriparatide, works similarly but has a slightly different signaling pattern. Clinical trial data suggests abaloparatide may produce better hip bone density gains — which matters because hip fractures are the most dangerous ones.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">This is a daily subcutaneous injection for up to two years, which is a real commitment. There is a black box warning about a theoretical bone cancer risk that came from rat studies at very high doses — this has not been observed in humans, but the warning limits lifetime use. It is also expensive and not always covered by insurance. The drug genuinely works for what it is prescribed for, but it requires medical supervision, bone density monitoring, and a planned transition to a follow-up medication. Net: one of the most effective tools available for severe osteoporosis — but it requires a doctor, a plan, and realistic expectations about the commitment involved.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 2</div>
        <h3 className="reta-overview__profile-heading">The Athlete — Bone density as a performance and injury-prevention concern</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I&rsquo;ve had stress fractures before and want better bone density. Could something like this help me recover faster or make my bones stronger?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>It demonstrably increases bone mineral density</strong><br />The clinical data is real — abaloparatide produces measurable increases in bone density at the spine and hip. For an athlete who has struggled with stress fractures, low bone density, or inadequate bone adaptation to training load, that mechanism is genuinely interesting on paper.</li>
          <li><strong>Potential link to bone remodeling signals</strong><br />Athletes with RED-S (relative energy deficiency in sport) or those coming off anorexic phases often have suppressed bone formation. The mechanism that abaloparatide triggers — stimulating osteoblasts, the cells that build bone — overlaps with what those athletes are missing. The curiosity is pharmacologically logical even if the application isn&rsquo;t.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">There is zero evidence that abaloparatide improves bone health in athletes with normal bone density. Every trial enrolled patients with established osteoporosis and high fracture risk. The drug&rsquo;s benefits are demonstrated in a diseased population and cannot be extrapolated to healthy athletic bone. Additionally, the bone cancer warning is a real constraint — this is not a compound anyone should use for marginal gain. If stress fractures are recurring, the answer is nutritional and training management, not a bone-building drug designed for severe disease. Net: mechanistically interesting to think about, completely inappropriate as a sports application, and carries a real warning label that should end the conversation.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 3</div>
        <h3 className="reta-overview__profile-heading">The Biohacker — Bone density as a longevity marker and aging intervention</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;Bone density is one of the best predictors of longevity outcomes. I&rsquo;m in my 40s with early-stage density loss. Is there a case for using something like this as a proactive aging intervention?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>Bone density as a longevity lever</strong><br />Hip fracture in older adults is strongly correlated with mortality — up to 30% of patients die within a year. Bone density at 50 predicts fracture risk at 70. From a longevity perspective, proactive bone maintenance is rational thinking, and abaloparatide represents the most potent anabolic bone intervention currently available.</li>
          <li><strong>Upstream mechanism — direct osteoblast stimulation</strong><br />Abaloparatide signals through the parathyroid hormone receptor in a conformation that favors bone-building over bone-breakdown. For someone interested in upstream levers rather than downstream symptom management, activating the cells that actually construct bone matrix is a compelling mechanistic story.</li>
          <li><strong>Sequential therapy model as a protocol template</strong><br />The prescribed abaloparatide-then-bisphosphonate sequence demonstrates that bone gains can be built and locked in — a two-phase approach that biohackers are drawn to as a model for intervention design.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">The longevity reasoning is intellectually solid but the application is wrong. Abaloparatide was studied in postmenopausal women with established osteoporosis — a population whose baseline bone metabolism differs substantially from a healthy person in their 40s. There is no evidence it provides additive benefit to normal bone, and the osteosarcoma black box — lifetime use capped at 2 years across this entire drug class — makes it a finite, one-time intervention. You cannot stack it, repeat it, or use it indefinitely. The smarter longevity approach is resistance training, adequate calcium and vitamin D, monitoring DEXA scans, and reserving this class of drug for when the data genuinely shows you need it. Net: correctly identified as a powerful lever, but the evidence and safety constraints mean it is most valuable as a known option to deploy if bone density becomes clinically concerning — not as a proactive optimization tool.</p>
      </div>

      <div className="reta-overview__bottom">
        <p className="reta-overview__bottom-heading">The honest bottom line</p>
        <div className="reta-overview__bottom-cols">
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What Abaloparatide is NOT</p>
            <ul className="reta-overview__bottom-list">
              <li>Not a supplement or wellness compound — it is a prescription-only Rx drug</li>
              <li>Not appropriate for anyone without diagnosed osteoporosis or high fracture risk</li>
              <li>Not a performance-enhancing or body-composition compound</li>
              <li>Not a repeatable intervention — lifetime use of this drug class is capped at 2 years total</li>
              <li>Not something with a meaningful off-label or community use case</li>
              <li>Not proven to benefit healthy bone or prevent age-related density loss in normal populations</li>
            </ul>
          </div>
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What makes it interesting</p>
            <ul className="reta-overview__bottom-list">
              <li>One of the only drugs that actively builds new bone rather than just slowing breakdown</li>
              <li>Strong clinical trial data showing real fracture reduction in high-risk patients</li>
              <li>More selective bone-building signal than the older drug in this class (teriparatide)</li>
              <li>Sequential therapy model — build density, then lock it in — is genuinely elegant</li>
              <li>Demonstrates that targeting a hormone receptor in a specific conformation can shift a biological outcome in a clinically meaningful direction</li>
            </ul>
          </div>
        </div>
      </div>

    </div>
  );
}
